The ASCO Post

The ASCO Post News and views from the world of clinical oncology and hematology

THE ASCO POST delivers timely and unbiased reports on major oncology meetings across the globe, including ASCO's annual meeting and regional symposia. Additionally, this newspaper-style publication provides readers with important summaries of evidence-based clinical literature from both general and specialty journals (fully sourced with links to original reports); notable research, data, and liter

ature with application in the clinic, including cost considerations/implications; columns from ASCO's membership with perspective on developments in oncology, quality cancer care, technology, electronic health records, and expert opinion on the state and economics of cancer care.

Risk-Reducing Surgeries Improve Survival for Younger Patients With Breast Cancer Who Are BRCA Carriers, Study Finds ...
01/15/2025

Risk-Reducing Surgeries Improve Survival for Younger Patients With Breast Cancer Who Are BRCA Carriers, Study Finds

Patients with early-onset breast cancer (aged 40 or younger at diagnosis) who have BRCA1 and/or BRCA2 pathogenic or likely pathogenic variants had improved overall survival by undergoing risk-reducing...

Trends in Early-Onset Colorectal Cancer
01/13/2025

Trends in Early-Onset Colorectal Cancer

As reported in The Lancet Oncology by Sung et al, analysis of international population–based cancer registry data indicate an increase in the incidence of colorectal cancer among younger persons (age ...

Anthracyclines Plus Taxane-Based Chemotherapy for Certain Patients at High Risk for Breast Cancer Recurrence
01/10/2025

Anthracyclines Plus Taxane-Based Chemotherapy for Certain Patients at High Risk for Breast Cancer Recurrence

Patients with early-stage, hormone receptor–positive, HER2-negative breast cancer who are at high risk for recurrence may benefit from adjuvant taxane and anthracycline-containing therapy more than fr...

Imlunestrant, Alone and Combined With Abemaciclib, Effective in ESR1-Mutated Breast Cancer
01/08/2025

Imlunestrant, Alone and Combined With Abemaciclib, Effective in ESR1-Mutated Breast Cancer

Imlunestrant, an investigational next-generation oral selective estrogen receptor degrader, significantly improved progression-free survival vs standard of care in patients with ESR1-mutated breast ca...

Studies Point to the Role of Diet in Hematologic Malignancies
01/06/2025

Studies Point to the Role of Diet in Hematologic Malignancies

According to research reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, a link seems to exist between hematologic malignancies and dietary components. The spea...

FDA Grants Accelerated Approval to Encorafenib Combination for BRAF V600E–Mutant Metastatic Colorectal Cancer
01/03/2025

FDA Grants Accelerated Approval to Encorafenib Combination for BRAF V600E–Mutant Metastatic Colorectal Cancer

On December 20, 2024, the U.S. Food and Drug Administration granted accelerated approval to encorafenib (Braftovi) in combination with cetuximab and modified fluorouracil, leucovorin, and oxaliplatin ...

Novel Oncolytic Immunotherapy Yields Durable Responses in High-Risk Bladder Cancer
01/03/2025

Novel Oncolytic Immunotherapy Yields Durable Responses in High-Risk Bladder Cancer

A novel immunotherapy may offer a new option for patients with bladder cancer who no longer respond to bacillus Calmette-Guérin, according to a study presented at the 2024 Society of Urologic Oncology...

ASCO: Clinical Advances in Melanoma TreatmentAllison Betof Warner, MD, reviews important research and FDA approvals in 2...
01/02/2025

ASCO: Clinical Advances in Melanoma Treatment
Allison Betof Warner, MD, reviews important research and FDA approvals in 2024 and looks ahead to 2025.

Allison Betof Warner, MD, PhD, on TIL Therapy for Advanced Melanoma: Innovative Clinical Advances in Treatment Thematic Newsreels Advertisement Allison Betof Warner, MD, PhD, reviews important clinical research in the treatment of advanced melanoma, including tumor-infiltrating lymphocyte (TIL) ther...

SEQUOIA 5-Year Follow-up: Zanubrutinib vs Bendamustine/Rituximab in Treatment-Naive CLL/SLL
01/01/2025

SEQUOIA 5-Year Follow-up: Zanubrutinib vs Bendamustine/Rituximab in Treatment-Naive CLL/SLL

As reported in the Journal of Clinical Oncology by Shadman et al, 5-year follow-up of the phase III SEQUOIA trial demonstrated that zanubrutinib continued to show a progression-free survival benefit o...

Understanding the Link Between Obesity and Cancer
12/30/2024

Understanding the Link Between Obesity and Cancer

Obesity is linked to the development of several major chronic diseases, including coronary artery disease, diabetes mellitus, and hypertension, as well as at least 12 major solid tumor cancers (includ...

Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally ...
12/26/2024

Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC

In a phase II trial reported in The Lancet Oncology, Heinzerling et al explored the efficacy of primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemotherapy...

Lenvatinib/Pembrolizumab vs Chemotherapy in Advanced Endometrial Cancer
12/23/2024

Lenvatinib/Pembrolizumab vs Chemotherapy in Advanced Endometrial Cancer

As reported in Journal of Clinical Oncology by Marth et al, the phase III European Network of Gynaecological Oncological Trial-en9/LEAP-001 study evaluated the impact of first-line lenvatinib/pembroli...

A Diagnosis of Lymphoma Has Changed My Life
12/20/2024

A Diagnosis of Lymphoma Has Changed My Life

“I was 35 when I was told that I had CD20-positive Hodgkin lymphoma. My oncologist assured me that although the disease was rare, it was treatable—and even curable. With the memory of my dying father ...

Low Omega-6/High Omega-3 Diet and Fish Oil Supplementation May Help Slow Prostate Cancer Growth
12/18/2024

Low Omega-6/High Omega-3 Diet and Fish Oil Supplementation May Help Slow Prostate Cancer Growth

Researchers have found that dietary changes in combination with fish oil supplementation may help reduce cancer cell growth in patients with prostate cancer undergoing active surveillance.

Imlunestrant, Alone and Combined With Abemaciclib, Effective in ESR1-Mutated Breast Cancer
12/16/2024

Imlunestrant, Alone and Combined With Abemaciclib, Effective in ESR1-Mutated Breast Cancer

Imlunestrant, an investigational next-generation oral selective estrogen receptor degrader, significantly improved progression-free survival vs standard of care in patients with ESR1-mutated breast ca...

Onvansertib With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer
12/13/2024

Onvansertib With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer

In a phase II trial reported in the Journal of Clinical Oncology, Ahn et al found the combination of the PLK1 inhibitor onvansertib with FOLFIRI (fluorouracil, leucovorin, and irinotecan) and bevacizu...

Preclinical Findings Show Ketogenic Diet Enhances CAR T-Cell Function, Improves Tumor Control
12/11/2024

Preclinical Findings Show Ketogenic Diet Enhances CAR T-Cell Function, Improves Tumor Control

Findings from a series of studies conducted in mice, human tissues, and healthy volunteers suggest that a ketogenic diet may enhance the effectiveness of chimeric antigen receptor (CAR) T-cell therapy...

Increase in Young-Onset Pancreatic Cancer May Be Due to Overdiagnosis of Early-Stage Endocrine Cancer
12/09/2024

Increase in Young-Onset Pancreatic Cancer May Be Due to Overdiagnosis of Early-Stage Endocrine Cancer

An analysis of pancreatic cancer in young adults (aged 15–39) has found that although there is an increase in incidence, the mortality rate remains stable. According to Patel et al, who published thei...

Address

Huntington, NY

Website

Alerts

Be the first to know and let us send you an email when The ASCO Post posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category